Cytek® Biosciences (CTKB) Reports Prelim FY24 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. AXP
9. TMUS
10. SPY

Go back to Cytek® Biosciences (CTKB) Reports Prelim FY24 Results

Cytek Biosciences Announces Preliminary Full Year 2024 Revenue Results

January 15, 2025 8:00 AM EST

FREMONT, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced preliminary, unaudited revenue results for the full year ended December 31, 2024.

Cytek expects its full year revenue for 2024 to be between $200 million and $201 million, representing 4% growth over Cyteks 2023 revenue of $193.0 million. This included a negative foreign exchange impact of approximately $1.0 million. Expected fourth quarter revenue of $57 million to $58 million represents growth of 11% to 13% compared to the third quarter of 2024 and decline of 2% to flat compared to a strong fourth quarter of 2023. The... More